|
|
|
|
Overviews
Highly Effective Reduction of C-Reactive Protein in Patients
with Coronary Heart Disease by Extracorporeal Low-Density Lipoprotein Apheresis
Wieland E, Schettler
V, Armstrong VW.
Atherosclerosis. 2002;162:187-191.
Low-Density Lipoprotein Apheresis in the Treatment of Atherosclerosis
and Other Potential Uses
Moriarty PM, Gibson CA.
Curr Atheroscler Rep. 2001;3:156-162.
Effect of HELP-LDL-Apheresis on Outcomes in Patients With
Advanced Coronary Atherosclerosis and Severe Hypercholesterolemia
Park J-W, Merz M, Braun P.
Atherosclerosis. 1998;139:401-409.
Long-Term Effect of Low-Density Lipoprotein Apheresis on
Plasma Lipoproteins and Coronary Heart Disease in Native Vessels and Coronary Bypass
in Severe Heterozygous Familial Hypercholesterolemia
Richter WO, Donner MG, Höfling B, Schwandt P.
Metabolism. 1998;47:863-868.
Safety and Effectiveness of Long-Term LDL-Apheresis in
Patients at High Risk
Thiery J, Seidel D.
Curr Opinion Lipidol. 1998;9:521-526.
Abstracts
The Efficacy and Safety of the New Heparin-Induced
Extracorporeal Low-Density Lipoprotein Precipitation System (Plasmat Futura) in
Comparison With the Currently Used System (Plasmat Secura)
Blessing F, Wang Y, Nagel D, Seidel D.
Ther Apher Dial. 2004;8:33-38.
This study examined whether the heparin-induced apheresis system, Plasmat Futura,
was comparable to the Plasmat Secura system in efficiently removing atherogenic
components, among other criteria, including clinical safety. Results demonstrate
that the Plasmat Futura system is easy to use, displays no adverse events, and is
comparable to Plasmat Secura in its ability to remove proatherogenic plasma factors.
Click for full abstract.
Heparin-Induced Extracorporeal Low-Density Lipoprotein Precipitation
Mellwig KP.
Ther Apher Dial. 2003;7:365-369.
The heparin-induced method of LDL-apheresis improved coronary vasodilatation capacity
within 24 hours, producing significant reductions in total cholesterol, LDL-C, and
fibrinogen.
Click for full abstract.
Long-Term Prevention of Premature Coronary Atherosclerosis in Homozygous Familial
Hypercholesterolemia
Jaeger BR, Tsobanelis T, Bengel F, Schwaiger S, Seidel D.
J Pediatr. 2002;141:125-128.
This case study of a 22-year-old woman with homozygous familial hypercholesterolemia
demonstrates the safety and efficacy of combined statins and LDL-apheresis using
the heparin-induced method.
Click for full abstract.
Intravascular Ultrasound Evaluation of Coronary Plaque Regression by Low Density
Lipoprotein-Apheresis Familial Hypercholesterolemia: the Low Density Lipoprotein-Apheresis
Coronary Morphology and Reserve Trial (LACMART)
Matsuzaki M, Hiramori K, Imaizumi T, et al.
J Am Coll Cardiol. 2002;40:228-230.
This trial assessed the effects of LDL-apheresis for regression of coronary plaque
in familial hypercholesterolemia using coronary angiography and intravascular ultrasound.
The group that received medication and LDL-apheresis showed 28.4% reduction in total
cholesterol, whereas the group that received medication showed no changes in cholesterol
levels.
Click for full abstract.
Evidence for Maximal Treatment of Atherosclerosis: Drastic Reduction of Cholesterol
and Fibrinogen Restores Vascular Homeostasis
Jaeger BR.
Ther Apher. 2001;5:207-211.
This article summarized the clinical and biochemical evidence for maximal treatment
of atherosclerosis by a simultaneous 60% to 70% reduction of plasma LDL cholesterol,
fibrinogen, and lipoprotein a (LPa) concentrations with statins and LDL-apheresis
using the heparin-induced method. Potential future applications are also discussed.
Click for full abstract.
Consistent Lowering of Clotting Factors for the Treatment of Acute Cardiovascular
Syndromes and Hypercoagulability: A Different Pathophysiological Approach
Jaeger BR, Goehring P, Schirmer J, et al.
Ther Apher. 2001;5:252-259.
The use of the heparin-induced method of LDL-apheresis in patients with acute cardiovascular
syndromes makes a controlled, immediately effective reduction of clotting factors
possible and induces subsequent positive effects on plasma viscosity, erythrocyte
aggregation, and microcirculation.
Click for full abstract.
C-Reactive Protein and Other Markers of Inflammation Among Patients Undergoing
HELP LDL Apheresis
Moriarty PM, Gibson CA, Shih J, Matia MS.
Atherosclerosis. 2001;158:495-498.
This trial of familial hypercholesterolemic patients treated with LDL-apheresis
therapy using the heparin-induced method evaluates the short- and long-term effects
on C-reactive protein (CRP). After 6 months of therapy, pretreatment hsCRP showed
an overall mean level decrease of 49%, suggesting that LDL-apheresis rapidly decreases
serum hsCRP levels in the long term.
Click for full abstract.
Heparin-Mediated Extracorporeal LDL/Fibrinogen Precipitation—HELP—in
Coronary and Cerebral Ischemia
Jaeger BR, Marx P, Pfefferkorn T, Hamann G, Seidel D.
Acta Neurochir Suppl. 1999;73:81-84.
LDL-apheresis using the heparin-induced method is beneficial in the prevention and
therapy of myocardial infarction. This method is now studied in patients with cerebral
infarction. The heparin-induced method was found to be safe in patients with coronary
heart disease and allows controlled reduction of thrombogenic plasma compounds.
Click for full abstract.
Relationship Between Plasma Viscosity and the Severity of Coronary Heart Disease
Junker R, Heinrich J, Ulbrich H, et al.
Arterioscler Thromb Vasc Biol. 1998;18:870-875.
This is the first report on the relationship of plasma viscosity and the severity
of coronary heart disease. A positive relationship was found even after adjusting
groups for age, fibrinogen, and use of diuretics. Differences between patients without
any and with one stenosed vessel, as well as between patients with one and two stenosed
vessels, did not achieve significance.
Click for full abstract.
Status of Treatment of Vascular Dementia
Lechner H.
Neuroepidemiology. 1998;17:10-13.
Further improvement of dementia could be achieved by application of the LDL-apheresis
using the heparin-induced method to enhance the effect of hemorheologically active
drugs. Using the heparin-induced method, LDL, cholesterol, triglycerides, and fibrinogen
can be considerably lowered and may result in clinical improvement or slowing of
the progression of vascular dementia.
Click for full abstract.
Improvement of Coronary Vasodilatation Capacity Through Single LDL Apheresis
Mellwig KP, Baller D, Gleichmann U, et al.
Atherosclerosis. 1998;139:173-178.
This study assessed whether an acute effect upon coronary vasodilatation capacity
can be achieved through single LDL-apheresis using positron emission tomography
(PET). Plasma viscosity was reduced slightly, by 6.6%. PET demonstrated a 30% improvement
in coronary vasodilatation capacity after a single LDL-apheresis within 24 hours.
Click for full abstract.
Regression of Transplant Coronary Artery Disease During Chronic Low-Density
Lipoprotein-Apheresis
Park J-W, Merz M, Braun P.
J Heart Lung Transplant. 1997;16:290-297.
In long-term heart transplantation survivors with hyperlipidemia who have development
of a rapid progressive coronary artery disease, LDL-apheresis can encourage disease
regression.
Click for full abstract.
Peripheral Vasoactivity in Familial Hypercholesterolemic Subjects Treated With
Heparin-Induced Extracorporeal LDL Precipitation (HELP)
Stadler RW, Ibrahim SF, Lees RS.
Atherosclerosis. 1997;128:241-249.
The effect of LDL-apheresis on vasoactivity is examined in this review, which concludes
that therapy via the heparin-induced method improves vasoactivity in patients with
severe familial hypercholesterolemia.
Click for full abstract.
Additional Citations
Plasmalogen Phospholipids in Plasma Lipoproteins of Normolipidemic Donors and
Patients With Hypercholesterolemia Treated by LDL Apheresis
Brautigam C, Engelmann B, Reiss D, et al.
Atherosclerosis. 1996;119:77-88.
Click for full abstract.
Treatment of Hypercholesterolemia With Heparin-Induced Extracorporeal Low-Density
Lipoprotein Precipitation (HELP)
Lees RS, Holmes NN, Stadler RW, Ibrahim SF, Lees AM.
J Clin Apheresis. 1996;11:132-137.
Click for full abstract.
Long-Term Effect of LDL-Apheresis on Coronary Heart Disease
Richter WO, Donner MG, Schwandt P.
Acta Angiologica . 1996;2:147-151.
Full abstract not available.
HELP Apheresis Therapy in the Treatment of Severe Hypercholesterolemia: 10 Years
of Clinical Experience
Seidel D.
Artif Organs. 1996;20:303-310.
Click for full abstract.
Fast Transmission of Alterations in Plasma Phosphatidylcholine/Sphingomyelin
Ratio and Lyso Phosphatidylcholine Levels into Changes of Red Blood Cell Membrane
Phospholipid Composition After Low Density Lipoprotein Apheresis
Kulschar R, Engelmann B, Brautigam C, Duhm J, Thiery J, Richter WO.
Eur J Clin Invest. 1995;25:258-265.
Click for full abstract.
Regression of Transplant Coronary Artery Disease During Chronic HELP Therapy:
A Case Study
Park J-W, Vermeltfoort M, Braun P, May E, Merz M.
Atherosclerosis. 1995;115:1-8.
Click for full abstract.
Lack of Plasma Lipid Peroxidation During LDL-Apheresis by Heparin-Induced Extracorporeal
LDL-Precipitation
Wieland E, Schettler V, Creutzfeldt C, Kickbusch H, Schuff-Werner P.
Eur J Clin Invest. 1995;25:838-842.
Click for full abstract.
Reversible Reduction of Phospholipid Bound Arachidonic Acid After Low Density
Lipoprotein Apheresis: Evidence for Rapid Incorporation of Plasmalogen Phosphatidylethanolamine
into the Red Blood Cell Membrane
Engelmann B, Brautigam C, Kulschar R, et al.
Biochim Biophys Acta. 1994;1196:154-164.
Click for full abstract.
Advances in LDL-Apheresis for the Treatment of Severe Hypercholesterolemia
Gordon BR, Saal SD.
Curr Opin Lipidol. 1994;5:69-73.
Click for full abstract.
The HELP-LDL-Apheresis Multicentre Study, an Angiographically Assessed Trial
on the Role of LDL-Apheresis in the Secondary Prevention of Coronary Heart Disease.
II. Final Evaluation of the Effect of Regular Treatment on LDL-Cholesterol Plasma
Concentrations and the Course of Coronary Heart Disease
Schuff-Werner P, Gohlke H, Bartmann U, et al.
Eur J Clin Invest. 1994;24:724-732.
Click for full abstract.
No Evidence for Feedback Inhibition of Hepatic Apolipoprotein B (apo B) Production
After Extracorporeal Low Density Lipoprotein Precipitation as Determined by [1-
13C]leucine Infusion in Normal Volunteers
Arends J, Bier DM, Schafer G, Armstrong VW, et al.
Eur J Clin Invest. 1993;23:602-614.
Click for full abstract.
Lipid Apheresis by Hemoperfusion: In Vitro Efficacy and Ex Vivo Biocompatibility
of a New Low-Density Lipoprotein Adsorber Compatible With Human Whole Blood
Bosch T, Schmidt B, Blumenstein M, Gurland HJ.
Artif Organs. 1993;17:640-652.
Click for full abstract.
Long-Term Efficiency, Biocompatibility, and Clinical Safety of Combined Simultaneous
LDL-Apheresis and Haemodialysis in Patients With Hypercholesterolaemia and End-Stage
Renal Failure
Bosch TH, Thiery J, Gurland HJ, Seidel D.
Nephrol Dial Transplant . 1993;8:1350-1358.
Click for full abstract.
LDL Apheresis in the Treatment of Severe Hyperlipidemia
Gordon BR.
Primary Cardiol. 1993;19:53-56.
Full abstract not available.
Extracorporeal Treatment of Hypercholesterolemia
Olbricht CJ.
Nephrol Dial Transplant. 1993;8:814-820.
Click for full abstract.
Effect of Heparin-Induced Extracorporeal Low-Density Lipoprotein Precipitation
and Bezafibrate on Hemorheology and Clinical Symptoms in Cerebral Multiinfarct Disease
Walzl M.
Haemostasis. 1993;23:192-202.
Click for full abstract.
Apolipoprotein A-I and Apolipoprotein B Containing Lipoprotein Particles in
Coronary Patients Treated With Extracorporal Low Density Lipoprotein Precipitation
(HELP)
Koren E, Armstrong VW, Mueller G, et al.
Atherosclerosis. 1992;95:157-170.
Click for full abstract.
Human Serum Gangliosides in Hypercholesterolemia, Before and After Extracorporeal
Elimination of LDL
Senn H-J, Orth M, Fitzke E, Koster W, Wieland H, Gerok W.
Atherosclerosis. 1992;94:109-117.
Click for full abstract.
Biocompatibility of Four Plasmapheresis Membranes in Patients Treated for Hypercholesterolemia
Bohler J, Donauer K, Koster W, Schollmeyer PJ, Wieland H, Horl WH.
Am J Nephrol. 1991;11:479-485.
Click for full abstract.
Combined LDL Apheresis and Hemodialysis in a Patient With End-Stage Renal Disease
and Accelerated Coronary Atherosclerosis
Grutzmacher P, Vallbracht C, Scheuermann E, Kurz P, Schoeppe W.
ASAIO Trans. 1991;37:M435-M436.
Click for full abstract.
Regression of Carotid Plaques During Low Density Lipoprotein Cholesterol Elimination
Hennerici M, Kleophas W, Gries FA.
Stroke. 1991;22:989-992.
Click for full abstract.
LDL-Apheresis: Results of Longterm Treatment and Vascular Outcome
Keller C.
Atherosclerosis. 1991;86:1-8.
Click for full abstract.
Complement Activation and Depletion During LDL-Apheresis by Heparin-Induced
Extracorporeal LDL-Precipitation (HELP)
Würzner R, Schuff-Werner P, Franzke A, et al.
Eur J Clin Invest. 1991;21:288-294.
Click for full abstract.
Functional Characteristics of LDL Particles Derived from Various LDL-Apheresis
Techniques Regarding LDL-Drug-Complex
Schultis H-W, von Baeyer H, Neitzel H, Riedel E.
J Lipid Res. 1990;31:2277-2284.
Click for full abstract.
BACK TO TOP
|
 |
 |
|